Persist AI
Persist accelerates long-acting drug development by 50% using AI.
Persist accelerates long-acting drug development by 50% using AI.
Persist AI, founded with a mission to revolutionize drug formulation, leverages AI-driven automation to significantly reduce the time required for developing long-acting drug injections for chronic diseases like cancer and diabetes. Their core vision is to expedite pharmaceutical innovation, making treatments more accessible and affordable. Persist AI offers an AI-enabled cloud formulation lab that allows discovery teams to create formulations up to 10 times faster and cheaper. Their services include high-throughput formulation screening, enabling the development of up to 1,000 formulations per month.
Notable figures associated with Persist AI include experts in AI and pharmaceutical sciences, although specific names are not provided. The company has attracted attention from investors focused on healthcare innovation. Persist AI's key achievements include reducing drug formulation development time from five years to approximately two years, representing a 50% reduction. This breakthrough has the potential to significantly impact the pharmaceutical industry by accelerating the availability of long-lasting treatments for chronic diseases, ultimately improving patient outcomes and reducing healthcare costs.
Companies similar to Persist AI include Potion, Model Medicines, Latent and Artos.
Persist AI was founded in 2022.
Persist AI's headquarters is located in Woodland, CA, US.
Persist AI's most recent funding round was for $4M (USD) in April 2023.
As of Apr 12, 2023, Persist AI has disclosed funding of $4.5M (USD). Undisclosed round amounts are excluded.
Persist AI has 8 employees as of Feb 4, 2024.
Artos
artosai.com
